DSP Quant Fund
The scheme seeks to deliver superior returns as compared to the underlying benchmark over the medium to long term through investing in equity and equity related securities. The portfolio of stocks will be selected, weighed and rebalanced based on a quant model theme.
Growthvine rating: 2/5 — ranked #118 of 186 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹19.61 (as of 2026-10-23) |
|---|
| AUM | ₹767 Cr |
|---|
| Expense ratio | 1.31% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Aparna Karnik |
|---|
| Exit load | 0 |
|---|
Performance & risk
| 5-year annualised return | 3.12% |
|---|
| Sharpe ratio | 0.04 |
|---|
| Standard deviation | 14.76% |
|---|
| Max drawdown | −32.69% |
|---|
| Alpha | -3.39 |
|---|
| Beta | 0.89 |
|---|
Over 5 years, captured 47.3% of NIFTY Alpha 50's upside and 56.6% of its downside.
Market cap allocation
| Large cap | 63.1% |
|---|
| Mid cap | 36.9% |
|---|
| Small cap | 0.0% |
|---|
Concentration
| Top 5 holdings | 17.3% |
|---|
| Top 10 holdings | 31.0% |
|---|
| Total holdings | 40 |
|---|
Top holdings
- TREPS / Reverse Repo Investments — 4.7%
- ITC Ltd — 3.9%
- Infosys Ltd — 3.5%
- Bharti Airtel Ltd. — 3.5%
- TATA STEEL LIMITED — 3.4%
- HCL Technologies Ltd — 3.0%
- Federal Bank Ltd. — 3.0%
- Bajaj Auto Limited — 2.9%
- Nestle India Ltd. — 2.8%
- Torrent Pharmaceuticals Ltd. — 2.5%
Top sectors
- Pharma & Biotech — 16.0%
- Software & Services — 10.3%
- Automobile — 10.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −13.6% | Q4 (Bottom) | #156 of 167 |
| 2025 | 8.1% | Q1 (Top) | #32 of 132 |
| 2024 | 10.0% | Q4 (Bottom) | #81 of 86 |
| 2023 | 19.8% | Q4 (Bottom) | #64 of 66 |
| 2022 | −7.5% | Q4 (Bottom) | #50 of 55 |